ARKG is trading at $46.19 (+6.88%), driven by positive late-stage melanoma-vaccine results from Moderna and Merck lifting biotechnology and healthcare stocks.
- The personalized mRNA therapy met key goals for reducing melanoma recurrence and distant spread in more than 1,100 patients.
- Healthcare is also benefiting from defensive positioning as technology and semiconductor shares weaken; the healthcare sector is reported up 1.59%.